Exelixis Inc., of South San Francisco, and Roche AG, of Basel, Switzerland, said the European Commission approved Cotellic (cobimetinib) for use in combination with Roche's Zelboraf (vemurafenib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.